Inventor · disambiguated record
Federico Mingozzi
Also filed as: MINGOZZI FEDERICO
17 granted patents·26 pending applications·53 citations·filing 2007–2025
90Inventor score
Files withGENETHON24CHILDRENS HOSPITAL PHILADELPHIA7INST NAT SANTE RECH MED5PHILADELPHIA CHILDREN HOSPITAL2SPARK THERAPEUTICS INC2
Top patents by PatentIndex Score
43 records- 0192US9909142B2Composition and methods for highly efficient gene transfer using AAV capsid variantsCHILDRENS HOSPITAL PHILADELPHIA·Filed 2013·Granted Mar 6, 2018·24 cites·19 claims
- 0289US11421211B2Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2017·Granted Aug 23, 2022·4 cites·9 claims
- 0389US10392632B2AAV8 vector with enhanced functional activity and methods of use thereofWRIGHT JOHN FRASER·Filed 2012·Granted Aug 27, 2019·18 cites·22 claims
- 0487US11339406B2Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2017·Granted May 24, 2022·3 cites·20 claims
- 0577US12305187B2Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2022·Granted May 20, 2025·0 cites·19 claims
- 0676US12037362B2Hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropismGENETHON·Filed 2019·Granted Jul 16, 2024·1 cites·7 claims
- 0776US2022334126A1Aav vector and assay for anti-aav (adeno-associated virus) neutralizing antibodiesCHILDRENS HOSPITAL PHILADELPHIA·Filed 2022·Application pending·0 cites
- 0876US2025127930A1Hybrid regulatory elementsGENETHON·Filed 2024·Application pending·0 cites
- 0976US2024317814A1Hybrid Recombinant Adeno-Associated Virus Serotype Between AAV9 and AAVrh74 with Reduced Liver TropismGENETHON·Filed 2024·Application pending·0 cites
- 1075US2025270590A1Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2025·Application pending·0 cites
- 1173US10471132B2Treatment of hyperbilirubinemiaGENETHON·Filed 2015·Granted Nov 12, 2019·3 cites·19 claims
- 1270US2024043867A1Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2022·Application pending·0 cites
- 1369US11559589B2Compositions and methods for detection and modulation of T cell mediated immune responses against viral vectors utilized for gene therapyCHILDRENS HOSPITAL PHILADELPHIA·Filed 2018·Granted Jan 24, 2023·0 cites·6 claims
- 1469US9075044B2Compositions and methods for detection and modulation of T cell mediated immune responses against viral vectors utilized for gene therapyHIGH KATHERINE A·Filed 2007·Granted Jul 7, 2015·0 cites·5 claims
- 1567US2023414724A1Treatment of hyperbilirubinemiaGENETHON·Filed 2023·Application pending·0 cites
- 1665US11408899B2AAV vector and assay for anti-AAV (adeno-associated virus) neutralizing antibodiesCHILDRENS HOSPITAL PHILADELPHIA·Filed 2014·Granted Aug 9, 2022·0 cites·34 claims
- 1765US2022389399A1Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2022·Application pending·0 cites
- 1865US2023142731A1Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulinsINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 1963US2023190965A1Treatment of glycogen storage disease iiiGENETHON·Filed 2022·Application pending·0 cites
- 2062US12171843B2Hybrid regulatory elementsGENETHON·Filed 2019·Granted Dec 24, 2024·0 cites·13 claims
- 2162US11939590B1AAV vector compositions and methods for gene transfer to cells, organs and tissuesCHILDRENS HOSPITAL PHILADELPHIA·Filed 2018·Granted Mar 26, 2024·0 cites·19 claims
- 2262US2022380807A1Method for reducing the expression of nkcc1 in a subjectINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 2361US11279950B2Composition and methods for highly efficient gene transfer using AAV capsid variantsCHILDRENS HOSPITAL PHILADELPHIA·Filed 2018·Granted Mar 22, 2022·0 cites·17 claims
- 2460US2021040503A1Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2020·Application pending·0 cites
- 2560US2022228167A1Peptide-Modified Hybrid Recombinant Adeno-Associated Virus Serotype Between AAV9 and AAVrh74 with Reduced Liver Tropism and Increased Muscle TransductionGENETHON·Filed 2019·Application pending·0 cites
- 2659US2021246469A1Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulinsINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 2756US11541131B2Treatment of glycogen storage disease IIIGENETHON·Filed 2018·Granted Jan 3, 2023·0 cites·21 claims
- 2856US11427836B2Method for reducing the expression of NKCC1 in a subjectINST NAT SANTE RECH MED·Filed 2018·Granted Aug 30, 2022·0 cites·15 claims
- 2956US2015320886A1Compositions and methods for detection and modulation of t cell mediated immune responses against viral vectors utilized for gene therapyPHILADELPHIA CHILDREN HOSPITAL·Filed 2015·Application pending·0 cites
- 3054US2022213505A1INDUCING IMMUNE TOLERANCE BY rAAV VECTORSUNIV PARIS·Filed 2020·Application pending·0 cites
- 3153US2021228738A1Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulinsINST NAT SANTE RECH MED·Filed 2017·Application pending·0 cites
- 3252US2025041448A1Gene Therapy of Fibroblast Growth Factor 23 Related Hypophosphatemic DiseasesGENETHON·Filed 2020·Application pending·0 cites
- 3350US2023040275A1Secretable protein induced immune tolerization and treatment of autoimmune, allergic and other diseases and disordersSPARK THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3449US2019374619A1Treatment of hyperbilirubinemiaGENETHON·Filed 2019·Application pending·0 cites
- 3547US2015111955A1Aav vector compositions and methods for gene transfer to cells, organs and tissuesPHILADELPHIA CHILDREN HOSPITAL·Filed 2013·Application pending·0 cites
- 3647US2022162640A1Hybrid promoters for muscle expressionGENETHON·Filed 2020·Application pending·0 cites
- 3746US2019390224A1Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2017·Application pending·0 cites
- 3846US2022331408A1Treatment of glycogen storage disease (gsd)GENETHON·Filed 2020·Application pending·0 cites
- 3945US2022011308A1In vitro assay for detecting enhancers and inhibitors of adeno associated virus (aav) vector transduction and/or detecting or quantitating anti-aav binding antibodiesSPARK THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4044US11376321B2Method for removing anti-AAV antibodies from a blood-derived compositionGENETHON·Filed 2018·Granted Jul 5, 2022·0 cites·17 claims
- 4143US2023033268A1Chimeric polypeptides and uses thereofGENETHON·Filed 2020·Application pending·0 cites
- 4243US2021292724A1Mini-gde for the treatment of glycogen storage disease iiiGENETHON·Filed 2019·Application pending·0 cites
- 4340US10640785B2Virus vectors for highly efficient transgene deliveryCHILDRENS HOSPITAL PHILADELPHIA·Filed 2012·Granted May 5, 2020·0 cites·28 claims
Join the waitlist — get patent alerts
Get an alert when Federico Mingozzi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →